<DOC>
	<DOCNO>NCT02556905</DOCNO>
	<brief_summary>The main purpose REVLIMID® DUE ( Drug Use Examination ) collect evaluate safety information Korean Multiple Myeloma patient treat REVLIMID® accord approved package insert , approval marketing authorization new drug Korea . In addition , efficacy information REVLIMID® clinical practice collect evaluate . This DUE multi-centre , observational non-interventional post-marketing surveillance . The patient recruit Drug Use Examination initiation Post Marketing Surveillance ( contract institution ) Patient Access Program ( PAP ) perform REVLIMID® reimbursement . Total 624 patient enrol PMS 07Sep2016 . Validation process eligibility safety assessment conduct site monitoring process 07Dec2016 . REVLIMID® DUE investigate frequency change Adverse Events ( AEs ) /Adverse Drug Reactions ( ADRs ) , Serious Adverse Events ( SAEs ) /Serious Adverse Drug Reactions ( SADRs ) , unexpected AE/ADR unexpected SAE/SADR , scrutinize factor influence safety &amp; efficacy drug . It necessary examine patient ' demographic baseline characteristic , medical history , status REVLIMID® treatment , concomitant medication evaluation safety final efficacy ( best response ) assessment .</brief_summary>
	<brief_title>A Study Collect Evaluate Safety Efficacy Information Korean Multiple Myeloma Patients Treated With REVLIMID® , After Approval Marketing Authorization New Drug Korea</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Korean male female diagnose Multiple Myeloma Inpatients patient REVLIMID® Drug Use Examination period intend treat REVLIMID ® Patients register Risk Management Program Celgene There 's exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Observational</keyword>
	<keyword>Korea</keyword>
	<keyword>Post Marketing Surveillance [ PMS ]</keyword>
</DOC>